Precision in Practice: A Master Class on PARPi Combinations, Testing Strategies, and Toxicity Management in Metastatic Prostate Cancer

San Francisco, CA US
February 26, 2026

Click the Register/Take Course button to complete the evaluation and get your certificate.

This activity aims to enhance learners’ knowledge and competence in selecting, sequencing, and managing PARP inhibitor-based therapies for metastatic prostate cancer (mPC) through guideline-concordant testing, informed clinical decision-making based on biomarker results, and proactive toxicity mitigation strategies—ultimately improving patient outcomes.

Not an official event of the 2026 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education.

Target Audience

This activity is intended for community oncologists, urologists, oncology nurses and nurse practitioners, physician associates, pharmacists, and other healthcare professionals involved in the care and treatment of patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate genetic testing workflows in concordance with guideline recommendations for all HRR mutations to identify patients who may benefit from PARP inhibitor-based therapy.
  • Evaluate efficacy, treatment sequencing, and subgroup data from recent trials of PARPi combinations in mPC, and assess their implications across BRCA and non-BRCA HRR mutation populations
  • Formulate patient care plans with PARP inhibitor-based combination regimens for the treatment of patients with mPC, taking into account recent guideline updates for sequencing, expert recommendations, and recent data, including patient subgroup data
  • Employ multidisciplinary strategies for ongoing therapy management to mitigate and manage adverse events associated with PARPi combination regimens, thereby improving quality of life, adherence, and outcomes in patients with mPC
  • Integrate strategies to identify and address barriers to appropriate genetic and biomarker testing for patients with mPC, including testing workflows and the role of the multidisciplinary care team

You may also be interested in

Prostate Cancer Management Simulator
By working through a series of realistic case scenarios, you will experience how to manage a variety of kidney cancer presentations over time. As you make decisions, you will receive expert corrective mentoring from virtual colleagues to help you recognize optimal decision-making patterns.
Recorded Presentation from Optimizing Patient Outcomes - Metastatic Castration-Resistant Prostate Cancer: Systemic Therapy Updates
It is important to stay up to date with the latest therapy options available, review the latest mCRPC systemic therapy recommendations, and understand the data behind them.
Additional information
Supporters: 

Supported by an educational grant from AstraZeneca. 
Supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
Course opens: 
02/26/2026
Course expires: 
03/31/2026
Event starts: 
02/26/2026 - 10:30pm EST
Event ends: 
02/26/2026 - 11:59pm EST
Add to calendar: 
Marriott Marquis San Francisco
780 Mission Street
Room: SoMa - second level
San Francisco, CA 94103
United States

Wassim Abida, MD, PhD
Director of Translational Research, Prostate Cancer
Associate Member, Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Nabil Adra, MD, MS
Associate Professor of Clinical Medicine
Associate Professor of Urology
Program Leader, Genitourinary Oncology
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana

Neeraj Agarwal, MD, FASCO
Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
HCI Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Kristine Peregrino Lacuna, MD
Assistant Attending
Genitourinary Medical Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Full disclosure of faculty relationships will be made prior to the activity.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-26-015-L01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Available Credit

  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
Please login or register to take this course.

Click the Register/Take Course button to complete the evaluation and get your certificate.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing